Provide your full name, academic degree(s), institution, address, and email address. As the first author (presenting author), you will receive all future correspondence from ASCO regarding the status of your abstract. The information provided upon submission must belong to the first author.
- Agree to present the abstract if selected for presentation. (This includes being present during the scheduled time of a poster session.)
- Verify that your clinical research was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
- Authors must assign copyright of the abstract to ASCO (unless the author is a U.S. federal employee).
- All parties involved with the abstract must abide by the Confidentiality Policy.
- All parties involved with the abstract must agree to the Prior Presentation and Publication Policy.
Identification of Original Research
Indicate whether your abstract reports on original research. Original research means a systematic investigation designed for the purpose of expanding knowledge or understanding, including the analysis of data. For clarity, a clinical trial is original research under this definition and a summary or review of prior knowledge is not original research under this definition.
Identification of Clinical Trials
Indicate whether your research is a clinical trial. A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (National Institutes of Health [NIH] Office of Extramural Research. Accessed August 8, 2016).
Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the first author will be asked to provide the name of the registry and the trial registration number during the abstract submission process. The clinical trial number will be included as part of the published abstract.
Indicate whether the abstract was funded by the NIH, a pharmaceutical or biotechnology company, a foundation, or other source. NIH-sponsored studies are those that receive direct NIH funding for their conduct, including cooperative group trials. If the research is funded by a pharmaceutical, biotechnology, or tobacco company, please provide a contact person at the company.
Sponsorship by ASCO Member
Abstracts must be sponsored by an ASCO Member in good standing. You may sponsor your own abstract if you are an ASCO Full Member, Allied Physician/Doctoral Scientist, or Member in Training. If you are an ASCO Member in Training sponsoring your own abstract, you must have approval from your training program director. Only ASCO Full Members may sponsor more than one abstract. If you are an Affiliated Health Professional, Advanced Practice Provider, Practice Administrator, or Patient Advocate member, you must obtain sponsorship from an ASCO Full Member.
The title should objectively describe the study. Do not refer to study results or conclusions. ASCO reserves the right to edit conclusive titles.
Provide the full name, academic degree(s), institution, address, email address, and disclosure information for each coauthor. You may list up to 20 individual authors for each abstract.
Authoring Group Name
Listing a group name is optional. Do not list individual author names in this field. The group name will appear after the last author in the author string. It does not count toward the 20-author limit.
It is ASCO's policy to promote balance, independence, objectivity, and scientific rigor in all of its activities through the disclosure of financial interests and other relationships, and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in ASCO's Policy for Relationships With Companies (Conflict of Interest). All authors are expected to provide general disclosure information for 11 disclosure categories of relationship with for-profit health care companies.
The first author must include their disclosure information as well as that for all coauthors. The Coauthor Disclosure Form may be used by the first author to obtain disclosure information from coauthors. The first author must enter all disclosure information through the Abstract Submitter. Disclosure information for all authors will be distributed as part of ASCO’s Annual Meeting materials.
Additional Disclosure Questions for First, Last, and Corresponding Authors of Original Research
First, last, and corresponding authors are required to answer additional questions concerning their abstract for informational purposes only. All submissions are peer-reviewed.
Restrictions for Presenting Authors
If the first author is employed by a company as defined by the CMSS Code for Interactions with Companies (see definition of "Company" below), an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an oral abstract session or clinical science symposium. Oral abstract presenters will also be subject to the same disclosure review and management strategies as faculty, per ASCO’s Implementation Plan to Manage Relationships with Companies for CME Activities.
Company: “A for‐profit entity that develops, produces, markets, or distributes drugs, devices, services or therapies used to diagnose, treat, monitor, manage, and alleviate health conditions. This definition is not intended to include non‐profit entities, entities outside of the health care sector, or entities through which physicians provide clinical services directly to patients.”
The body of your abstract should describe the background, methods, results, and conclusions of your research. You may type your abstract directly into the text box, cut and paste from an existing document, or upload a text file of your abstract. Do not exceed 2,000 characters (approximately 300 to 350 words) for the total of your abstract title, body (including section titles), and table. The character count does not include spaces or author names or institutions. One data table is permitted per abstract. Illustrations and figures are not permitted.
Select the most appropriate track and subcategory for the abstract. When submitting your abstract, you will have the option of identifying a secondary subcategory for your abstract. The ASCO Scientific Program Committee has the authority to recategorize an abstract.
A $60 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Credit cards are the only accepted form of payment. Checks, wire transfers, and purchase orders will not be accepted. First authors from low-income countries, as defined by the World Bank, may apply for a payment waiver. Please email for more information.